Ranabir Sinha Roy

Statistics

Publications

Citations

3.3K

H-Index

Active since

1994

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Harvard University

Ranabir Sinha Roy is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, enzyme inhibition, and life sciences.

Publications per year

1994–2015

Publications

(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes

George R. Lankas, Barbara Leiting, Ranabir Sinha Roy et al. · Diabetes · 2005 · 491 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

James Mu, John Woods, Yun-Ping Zhou et al. · Diabetes · 2006 · 450 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

Stacey Conarello, Zhihua Li, John Ronan et al. · Proceedings of the National Academy of Sciences · 2003 · 350 citations · Full text

Life Sciences, Biochemistry, Endocrinology +17

The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides

Lan Zhu, Constantin Tamvakopoulos, Dan Xie et al. · Journal of Biological Chemistry · 2003 · 221 citations · Full text

Life Sciences, Biochemistry, Endocrinology +17

1–5 of 23